1. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.
2. Health Canada. Canada Health Act [Internet]. Canada.ca. 2004 [cited 2021 May 29]. Available from: https://www.canada.ca/en/health-canada/services/health-care-system/canada-health-care-system-medicare/canada-health-act.html
3. Impact HTA [Internet]. Impact-hta.eu. [cited 2021 May 29]. Available from: https://www.impact-hta.eu/country-vignettes
4. Nicod E, Whittal A, Drummond M, Facey K. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches. Orphanet J Rare Dis. 2020;15(1):189.
5. Richter T, Janoudi G, Amegatse W, Nester-Parr S. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR. Orphanet J Rare Dis [Internet]. 2018;13(1). Available from: http://dx.doi.org/10.1186/s13023-018-0762-1
6. Health Canada. National strategy for high cost drugs for rare diseases online engagement - Canada.Ca [Internet]. Canada.ca. 2021 [cited 2021 May 29]. Available from: https://www.canada.ca/en/health-canada/programs/consultation-national-strategy-high-cost-drugs-rare-diseases-online-engagement.html
7. Europa.eu. [cited 2021 May 29]. Available from: https://www.ema.europa.eu/en/about-us/brexit-united-kingdoms-withdrawal-european-union
8. Lee DK, Wong B. An orphan drug framework (ODF) for Canada. J Popul Ther Clin Pharmacol. 2014;21(1):e42-6.
9. Government of Canada, Canadian Institutes of Health Research, Institutes, Institute of Genetics. Supporting cutting-edge rare disease research [Internet]. Cihr-irsc.gc.ca. 2016 [cited 2021 May 29]. Available from: https://cihr-irsc.gc.ca/e/49695.html
10. Office of the Commissioner. Designating an orphan drug or biologic [Internet]. Fda.gov. 2021 [cited 2021 May 29]. Available from: https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products
11. Health Canada. Notice of Compliance (NOC) database [Internet]. Canada.ca. 2005 [cited 2021 May 29]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/database.html
12. Search orphan drug designations and approvals. [cited 2021 May 29]; Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
13. Reimbursement Review Reports [Internet]. Cadth.ca. 2015 [cited 2021 May 29]. Available from: https://www.cadth.ca/reimbursement-review-reports
14. INESSS [Internet]. Inesss.qc.ca. [cited 2021 May 29]. Available from: https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription.html
15. Brand Name Drug Negotiations Status [Internet]. Pcpacanada.ca. [cited 2021 May 29]. Available from: https://www.pcpacanada.ca/negotiations
16. Ministry of Health. Drug Coverage [Internet]. Gov.bc.ca. [cited 2021 May 29]. Available from: https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage
17. Alberta health - drug benefit list [Internet]. Bluecross.ca. [cited 2021 May 29]. Available from: https://idbl.ab.bluecross.ca/idbl/load.do
18. Home Page - Online Formulary 2021 [Internet]. Ehealthsask.ca. [cited 2021 May 29]. Available from: http://formulary.drugplan.ehealthsask.ca/SearchFormulary
19. Author’s Name. Pharmacare Program [Internet]. Gov.mb.ca. [cited 2021 May 29]. Available from: https://web22.gov.mb.ca/eFormulary/
20. Check medication coverage [Internet]. Ontario.ca. [cited 2021 May 29]. Available from: https://www.ontario.ca/page/check-medication-coverage/
21. Government of Ontario, Ministry of Health, Care L-T. Exceptional Access Program - Formulary - health care professionals - MOHLTC. 2009 [cited 2021 May 29]; Available from: https://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx
22. Médicaments [Internet]. Gouv.qc.ca. [cited 2021 May 29]. Available from: https://www.ramq.gouv.qc.ca/fr/professionnels/pharmaciens/medicaments/Pages/liste-medicaments.aspx
23. Government of New Brunswick, Canada. New Brunswick Drug Plans Formulary [Internet]. Gnb.ca. 2014 [cited 2021 May 29]. Available from: https://www2.gnb.ca/content/gnb/en/departments/health/MedicarePrescriptionDrugPlan/NBDrugPlan/ForHealthCareProfessionals/NewBrunswickDrugPlansFormulary.html
24. Novascotia.ca. [cited 2021 May 29]. Available from: https://novascotia.ca/dhw/pharmacare/formulary
25. Health and Community Services [Internet]. Gov.nl.ca. [cited 2021 May 29]. Available from: https://www.health.gov.nl.ca/health/prescription/newformulary.asp
26. PEI Pharmacare Formulary [Internet]. Princeedwardisland.ca. 2019 [cited 2021 May 29]. Available from: https://www.princeedwardisland.ca/en/information/health-pei/pei-pharmacare-formulary
27. Brandt J, Shearer B, Morgan SG. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare. J Pharm Policy Pract. 2018;11(1):28.
28. Espin J, Schlander M, Godman B, Anderson P, Mestre-Ferrandiz J, Borget I, et al. Projecting pharmaceutical expenditure in EU5 to 2021: Adjusting for the impact of discounts and rebates. Appl Health Econ Health Policy. 2018;16(6):803–17.
29. Health Canada. Project Orbis [Internet]. Canada.ca. 2021 [cited 2021 May 29]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/international-activities/project-orbis.html
30. Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372:m4856.
31. Khosla S, White R, Medina J, Ouwens M, Emmas C, Koder T, et al. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? F1000Res. 2018;7:111.
32. Toumi M, Jarosławski S, Sawada T, Kornfeld Å. The use of surrogate and patient-relevant endpoints in outcomes-based Market Access Agreements : Current debate: Current debate. Appl Health Econ Health Policy. 2017;15(1):5–11.
33. Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: Policy analysis from the European perspective. Value Health. 2020;23(4):425–33.
34. Cadth.ca. [cited 2021 May 29]. Available from: https://cadth.ca/sites/default/files/symp-2019/presentations/april15-2019/A1-presentation-elun.pdf
35. Raredisorders.ca. [cited 2021 May 29]. Available from: http://www.raredisorders.ca/content/uploads/EDRD-supplemental-process-background_24Oct2018_Final.pdf
36. Time to jump start rare disease drug strategy [Internet]. Raredisorders.ca. [cited 2021 Jul 16]. Available from: http://www.raredisorders.ca/time-to-jump-start-rare-disease-drug-strategy/